BLCO Stock Forecast & Price Target

Bausch & Lomb has shown a positive financial outlook with management raising its 2025 revenue guidance to between $5,050 million and $5,150 million, reflecting a 5-7% constant currency growth. The company forecasts adjusted EBITDA to increase to a range of $860 million to $910 million, while also anticipating foreign exchange benefits of $25 million for the full year. Additionally, there has been significant product performance, with MIEBO showcasing a remarkable 111% year-over-year prescription growth and a consistent increase in sales across its premium intraocular lens segments.

Bausch & Lomb's financial outlook is negatively affected by several fundamental factors, including its limited product pipeline and high leverage following its acquisition of Xiidra, which constrain long-term growth potential. Additionally, the company faces significant competitive pressures in a promotional market, alongside macroeconomic uncertainties impacting consumer spending and elective surgery volumes, particularly in cataract procedures and contact lenses. The ongoing litigation related to the company's former parent, Bausch Health Companies, adds further uncertainty, potentially inhibiting investor confidence and affecting stock performance.